Filtered By:
Drug: Taxotere

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 2210 results found since Jan 2013.

Ketoconazole for the Treatment of Docetaxel-Na ïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
CONCLUSION: Ketoconazole with corticosteroid could be an effective alternative for the treatment of mCRPC with a satisfactory PSA response and disease progression.PMID:34710984 | DOI:10.31557/APJCP.2021.22.10.3101
Source: Asian Pacific Journal of Cancer Prevention - October 29, 2021 Category: Cancer & Oncology Authors: Raden Indra Tresnanda Sawkar Vijay Pramod Ferry Safriadi Source Type: research

Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer
CONCLUSION: Though retrospective, our results showed an increased incidence of VBMs in bmCRPC patients after 2011. However, this was not associated with NHA exposure duration. The role of NHA exposure remains unclear and needs further investigation.PMID:35562276 | DOI:10.1016/j.clgc.2022.04.004
Source: Clinical Prostate Cancer - May 13, 2022 Category: Cancer & Oncology Authors: C édric Pobel Emeline Laurent Aline-Marie Florence Ga ëlle Fromont Gilles Calais B érengère Narciso Claude Linassier Mathilde Cancel Source Type: research

Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations
Clin Genitourin Cancer. 2022 Apr 29:S1558-7673(22)00090-8. doi: 10.1016/j.clgc.2022.04.014. Online ahead of print.ABSTRACTThe management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to systematically identify and review published economic evaluations (EEs) related to the treatment of mHSPC and assess their quality. A systematic search was performed of the PubMed and Cochrane databases. Three reviewers independently selected EEs by defined incl...
Source: Clinical Prostate Cancer - May 24, 2022 Category: Cancer & Oncology Authors: R émi Pelloux-Prayer Thomas Bataillard Antoine Thiery-Vuillemin Alexandre Vincent Philippe Fagnoni Virginie Nerich Source Type: research

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
J Clin Med. 2022 May 15;11(10):2783. doi: 10.3390/jcm11102783.ABSTRACTMetastatic castration-resistant prostate cancer (mCRPC) is the ultimately lethal form of prostate cancer. Docetaxel chemotherapy was the first life-prolonging treatment for mCRPC; however, the standard maximally tolerated dose (MTD) docetaxel regimen is often not considered for patients with mCRPC who are older and/or frail due to its toxicity. Low-dose metronomic chemotherapy (LDMC) is the frequent administration of typically oral and off-patent chemotherapeutics at low doses, which is associated with a superior safety profile and higher tolerability th...
Source: Clinical Prostate Cancer - May 28, 2022 Category: Cancer & Oncology Authors: Shruti Parshad Amanjot K Sidhu Nabeeha Khan Andrew Naoum Urban Emmenegger Source Type: research

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
CONCLUSION: Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.PMID:37700573 | DOI:10.1177/10600280231197459
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Natalie Mausey Zachery Halford Source Type: research

A Systematic Review of Vinorelbine for the Treatment of Breast Cancer
Abstract The purpose of this study was to investigate the efficacy and safety profile of vinorelbine‐based chemotherapy in different settings for the treatment of breast cancer. We performed a computerized search using combinations of the following keywords: “breast cancer”, “breast neoplasms”, “trial”, “vinorelbine” and “navelbine”. A total of 20 trials were included in this analysis, with a total of 5,080 patients accrued. Taxane was associated with enhanced overall survival (OS; p = 0.027) and response rate (RR; p = 0.037) as compared with vinorelbine in monotherapy, but did not show significan...
Source: The Breast Journal - January 1, 2013 Category: Cancer & Oncology Authors: Ying‐Chun Xu, Hong‐Xia Wang, Lei Tang, Yue Ma, Feng‐Chun Zhang Tags: Original Article Source Type: research

Functional Organ Preservation in Locally Advanced Laryngeal Squamous Cell Carcinoma: Is there a Role for Induction Chemotherapy?
Abstract: Concurrent chemoradiation (CRT) is currently the most effective strategy for organ preservation in locally advanced laryngeal squamous cell carcinoma (SCC) unsuitable for function-preserving surgery. The larynx preservation approach of induction chemotherapy followed by radiotherapy in responders is based on the hypothesis that tumours that show a satisfactory response to induction chemotherapy are more likely to respond to radiation-based treatment. This enables the use of chemotherapy response to identify patients who are more likely to achieve long-term disease control with organ-preserving therapies. An induc...
Source: Clinical Oncology - January 4, 2013 Category: Radiology Authors: S.W. Loo, K. Geropantas, T.W. Roques Tags: Overview Source Type: research

Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer.
CONCLUSION: Pertuzumab provided a more comprehensive inhibition of HER2-driven signalling pathways. When administered together with trastuzumab, pertuzumab represent a significant advancement for the treatment of HER2-positive metastatic breast cancer patients. PMID: 23881722 [PubMed - as supplied by publisher]
Source: Advances in Therapy - July 24, 2013 Category: Drugs & Pharmacology Authors: De Mattos-Arruda L, Cortes J Tags: Adv Ther Source Type: research

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
Conclusion This meta-analysis demonstrated evidence to support second-line chemotherapy in advanced gastric cancer.
Source: Annals of Oncology - October 29, 2013 Category: Cancer & Oncology Authors: Kim, H. S., Kim, H. J., Kim, S. Y., Kim, T. Y., Lee, K. W., Baek, S. K., Kim, T. Y., Ryu, M. H., Nam, B. H., Zang, D. Y. Tags: gastrointestinal tumors Source Type: research